Literature DB >> 15304589

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

M C Y de Wit1, H G de Bruin, W Eijkenboom, P A E Sillevis Smitt, M J van den Bent.   

Abstract

To determine the frequency of progressive MRI lesions shortly after radiotherapy for glioma with spontaneous improvement or stabilization, the authors studied a cohort of patients treated within two prospective phase III trials with radiotherapy only. In 9 out of 32 patients, the first post-radiotherapy MRI showed progressive enhancement. In 3 of these 9 the MRI improved or stabilized for 6 months without additional treatment. The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304589     DOI: 10.1212/01.wnl.0000133398.11870.9a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  137 in total

1.  Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Authors:  Sanath Kumar; Ali S Arbab; Rajan Jain; Jinkoo Kim; Ana C deCarvalho; Adarsh Shankar; Tom Mikkelsen; Stephen L Brown
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

Review 2.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

3.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Authors:  Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

4.  [Supportive care and palliation in patients with malignant gliomas].

Authors:  Stefan Oberndorfer; Heinz Lahrmann
Journal:  Wien Med Wochenschr       Date:  2006-06

5.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Authors:  Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

6.  Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Authors:  Morad Nasseri; Seymur Gahramanov; Joao Prola Netto; Rongwei Fu; Leslie L Muldoon; Csanad Varallyay; Bronwyn E Hamilton; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2014-02-11       Impact factor: 12.300

7.  EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Authors:  Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Authors:  Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

9.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

10.  Brain irradiation: effects on normal brain parenchyma and radiation injury.

Authors:  Pia C Sundgren; Yue Cao
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.